Rigel Pharmaceuticals Inc - Asset Resilience Ratio
Rigel Pharmaceuticals Inc (RIGL) has an Asset Resilience Ratio of 6.62% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RIGL current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Rigel Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Rigel Pharmaceuticals Inc.
Liquid Assets Composition Over Time
This chart breaks down Rigel Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Rigel Pharmaceuticals Inc (RIGL) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $34.51 Million | 6.62% |
| Total Liquid Assets | $34.51 Million | 6.62% |
Asset Resilience Insights
- Limited Liquidity: Rigel Pharmaceuticals Inc maintains only 6.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Rigel Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Rigel Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Rigel Pharmaceuticals Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Rigel Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.27% | $114.38 Million | $513.59 Million | +9.72pp |
| 2024-12-31 | 12.55% | $20.57 Million | $163.98 Million | -8.05pp |
| 2023-12-31 | 20.60% | $24.15 Million | $117.22 Million | -4.53pp |
| 2022-12-31 | 25.13% | $33.75 Million | $134.28 Million | -38.26pp |
| 2021-12-31 | 63.39% | $106.08 Million | $167.33 Million | +38.97pp |
| 2020-12-31 | 24.42% | $26.95 Million | $110.38 Million | -26.78pp |
| 2019-12-31 | 51.20% | $75.56 Million | $147.57 Million | +13.67pp |
| 2018-12-31 | 37.54% | $52.22 Million | $139.11 Million | -27.50pp |
| 2017-12-31 | 65.03% | $77.46 Million | $119.11 Million | -8.09pp |
| 2016-12-31 | 73.12% | $57.13 Million | $78.13 Million | +10.26pp |
| 2015-12-31 | 62.86% | $82.82 Million | $131.75 Million | -20.15pp |
| 2014-12-31 | 83.02% | $127.96 Million | $154.13 Million | -1.53pp |
| 2013-12-31 | 84.55% | $191.12 Million | $226.06 Million | -0.85pp |
| 2012-12-31 | 85.39% | $264.76 Million | $310.04 Million | -3.68pp |
| 2011-12-31 | 89.07% | $229.01 Million | $257.11 Million | -1.14pp |
| 2010-12-31 | 90.21% | $168.42 Million | $186.69 Million | +5.94pp |
| 2009-12-31 | 84.27% | $118.60 Million | $140.74 Million | +22.77pp |
| 2008-12-31 | 61.50% | $88.47 Million | $143.86 Million | +6.41pp |
| 2007-12-31 | 55.09% | $63.79 Million | $115.79 Million | +4.98pp |
| 2006-12-31 | 50.11% | $56.74 Million | $113.24 Million | +8.52pp |
| 2005-12-31 | 41.59% | $61.42 Million | $147.67 Million | -35.71pp |
| 2004-12-31 | 77.30% | $60.93 Million | $78.82 Million | +10.88pp |
| 2003-12-31 | 66.42% | $36.88 Million | $55.52 Million | +64.71pp |
| 2002-12-31 | 1.70% | $756.00K | $44.34 Million | -45.50pp |
| 2001-12-31 | 47.21% | $21.93 Million | $46.45 Million | +41.04pp |
| 2000-12-31 | 6.17% | $3.96 Million | $64.26 Million | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more